HRP20100402T1 - Formamidni derivati korisni kao ardrenoceptor - Google Patents

Formamidni derivati korisni kao ardrenoceptor Download PDF

Info

Publication number
HRP20100402T1
HRP20100402T1 HR20100402T HRP20100402T HRP20100402T1 HR P20100402 T1 HRP20100402 T1 HR P20100402T1 HR 20100402 T HR20100402 T HR 20100402T HR P20100402 T HRP20100402 T HR P20100402T HR P20100402 T1 HRP20100402 T1 HR P20100402T1
Authority
HR
Croatia
Prior art keywords
hydroxyphenyl
formylamino
hydroxyethylamino
methylpropyl
phenyl
Prior art date
Application number
HR20100402T
Other languages
English (en)
Inventor
Daniel Brown Alan
Edward Bunnage Mark
Alan Glossop Paul
James Kim
Alice Louise Lane Charlotte
Andrew Lewthwaite Russell
Anthony Price David
Original Assignee
Pfizer Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/IB2005/000619 external-priority patent/WO2005092840A1/en
Application filed by Pfizer Inc. filed Critical Pfizer Inc.
Publication of HRP20100402T1 publication Critical patent/HRP20100402T1/hr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/54—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C07C217/56—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by singly-bound oxygen atoms
    • C07C217/60—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by singly-bound oxygen atoms linked by carbon chains having two carbon atoms between the amino groups and the six-membered aromatic ring or the condensed ring system containing that ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D335/00—Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom
    • C07D335/02—Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/34—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups
    • C07C233/42—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring
    • C07C233/43—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring having the carbon atom of the carboxamide group bound to a hydrogen atom or to a carbon atom of a saturated carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/20—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/28—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton
    • C07C237/30—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton having the nitrogen atom of the carboxamide group bound to hydrogen atoms or to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/28—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton
    • C07C237/32—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton having the nitrogen atom of the carboxamide group bound to an acyclic carbon atom of a hydrocarbon radical substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/30—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/45—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups at least one of the singly-bound nitrogen atoms being part of any of the groups, X being a hetero atom, Y being any atom, e.g. N-acylaminosulfonamides
    • C07C311/46—Y being a hydrogen or a carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/26—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
    • C07C317/32—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/23—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
    • C07C323/39—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton at least one of the nitrogen atoms being part of any of the groups, X being a hetero atom, Y being any atom
    • C07C323/40—Y being a hydrogen or a carbon atom
    • C07C323/41—Y being a hydrogen or an acyclic carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/23—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
    • C07C323/39—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton at least one of the nitrogen atoms being part of any of the groups, X being a hetero atom, Y being any atom
    • C07C323/40—Y being a hydrogen or a carbon atom
    • C07C323/42—Y being a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36—Radicals substituted by singly-bound nitrogen atoms
    • C07D213/40—Acylated substituent nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
    • C07D217/06—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines with the ring nitrogen atom acylated by carboxylic or carbonic acids, or with sulfur or nitrogen analogues thereof, e.g. carbamates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/12—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring
    • C07D217/14—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring other than aralkyl radicals
    • C07D217/16—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring other than aralkyl radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/22—Bridged ring systems
    • C07D221/24—Camphidines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
    • C07D295/182—Radicals derived from carboxylic acids
    • C07D295/192—Radicals derived from carboxylic acids from aromatic carboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04—One of the condensed rings being a six-membered aromatic ring
    • C07C2602/08—One of the condensed rings being a six-membered aromatic ring the other ring being five-membered, e.g. indane
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2603/00—Systems containing at least three condensed rings
    • C07C2603/56—Ring systems containing bridged rings
    • C07C2603/58—Ring systems containing bridged rings containing three rings
    • C07C2603/70—Ring systems containing bridged rings containing three rings containing only six-membered rings
    • C07C2603/74—Adamantanes

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Hydrogenated Pyridines (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Spoj opće formule (1), naznačen time što skupina (CH2)n-C(=O)Q1 je na meta ili para položaju,- R1 i R2 se neovisno bira između H i C1-C4 alkila;- n je 0, 1 ili 2;- Q1 je skupina koju se bira između, gdje p je 1 ili 2, a q je 1 ili 2, gdje je navedena skupina izborno premoštena s jednim atomom ugljika, i skupine *-NR8-Q2-A, gdje Q2 je C1-C4 alkilen, R8 je H ili C1-C4 alkil, a A je piridil, C3-C10 cikloalkil, gdje je navedeni cikloalkil izborno premošten s jednim ili više atoma ugljika, tetrahidropiranil, piperidinil, tetrahidrotiopiranil ili skupina- R3, R4, R5, R6 i R7 su isti ili različiti i bira ih se između H, C1-C4 alkila, OR9, SR9, SOR9, SO2R9, halogena, CO2R9 CF3, CN, OCF3, SO2NR9R10, CONR9R10, NR9R10, NHCOR10 i fenila, izborno supstituiranog s 1 do 3 skupine, koje se bira između OR9, halogena i C1-C4 alkila;- R9 i R10 su isti ili različiti i bira ih se između H ili C1-C4 alkil, a * predstavlja točku vezanja na karbonilnu skupinu; ili, ako je to prikladno, njegove farmaceutski prihvatljive soli i/ili izomeri, tautomeri, solvati ili njihove izotopne varijante. Patent sadrži još 23 patentna zahtjeva.

Claims (24)

1. Spoj opće formule (1), [image] naznačen time što skupina (CH2)n-C(=O)Q1 je na meta ili para položaju, – R1 i R2 se neovisno bira između H i C1-C4 alkila; – n je 0, 1 ili 2; – Q1 je skupina koju se bira između, [image] gdje p je 1 ili 2, a q je 1 ili 2, gdje je navedena skupina izborno premoštena s jednim atomom ugljika, [image] i skupine *-NR8-Q2-A, gdje Q2 je C1-C4 alkilen, R8 je H ili C1-C4 alkil, a A je piridil, C3-C10 cikloalkil, gdje je navedeni cikloalkil izborno premošten s jednim ili više atoma ugljika, tetrahidropiranil, piperidinil, tetrahidrotiopiranil ili skupina [image] – R3, R4, R5, R6 i R7 su isti ili različiti i bira ih se između H, C1-C4 alkila, OR9, SR9, SOR9, SO2R9, halogena, CO2R9 CF3, CN, OCF3, SO2NR9R10, CONR9R10, NR9R10, NHCOR10 i fenila, izborno supstituiranog s 1 do 3 skupine, koje se bira između OR9, halogena i C1-C4 alkila; – R9 i R10 su isti ili različiti i bira ih se između H ili C1-C4 alkil, a * predstavlja točku vezanja na karbonilnu skupinu; ili, ako je to prikladno, njegove farmaceutski prihvatljive soli i/ili izomeri, tautomeri, solvati ili njihove izotopne varijante.
2. Spoj u skladu s patentnim zahtjevom 1, naznačen time što Q1 je skupina *-NH-Q2-A, gdje A je cikloheksil ili adamantil.
3. Spoj u skladu s patentnim zahtjevom 1, naznačen time što Q1 je skupina *-NH-Q2-A, gdje A je skupina [image] gdje R3, R4, R5, R6 i R7 su isti ili različiti i bira ih se između H, C1-C4 alkila, OR9, SR9, SOR9, SO2R9, halogena, CN, CO2R9, CF3, OCF3, SO2NR9R10, CONR9R10, NR9R10, NHCOR10 i fenila, izborno supstituiranog s 1 do 3 skupine, koje se bira između OR9, halogena i C1-C4 alkila, uz uvjet da najmanje 2 od R3 do R7 su H; gdje R9 i R10 su isti ili različiti i bira ih se između H ili C1-C4 alkila.
4. Spoj u skladu s patentnim zahtjevom 3, naznačen time što Q1 je skupina *-NH-Q2-A, gdje A je skupina [image] gdje R3, R4, R5, R6 i R7 su isti ili različiti i bira ih se između H, OH, CH3, OCH3, OCF3, OCH2-CH3, SCH3, N(CH3)2, N(C=O)CH3, C(=O)NH2, COOCH3, SO2CH3 SO2NH2, CN, halogena, CF3, te fenila, izborno supstituiranog s OH.
5. Spoj u skladu s patentnim zahtjevom 1, naznačen time što A je skupina [image] gdje jedan od R3 do R7 je OH ili fenil supstituiran s OH.
6. Spoj u skladu s patentnim zahtjevom 1, naznačen time što A je naftil, izborno suspstituiran s OH.
7. Spoj u skladu s bilo kojim od patentnih zahtjeva 1 do 6, naznačen time što Q2 je -CH2-, -(CH2)2-, -(CH2)3-, -CH2-C(CH3)2- ili -C(CH3)2-.
8. Spoj u skladu s patentnim zahtjevom 7, naznačen time što Q2 je -CH2-.
9. Spoj u skladu s patentnim zahtjevom 1, naznačen time što Q1 je [image] gdje R3, R4, R5 i R6 su H.
10. Spoj u skladu s bilo kojim od patentnih zahtjeva 1 do 9, naznačen time što R1 je H ili C1-C4 alkil i R2 je C1-C4 alkil.
11. Spoj u skladu s patentnim zahtjevom 10, naznačen time što R1 je H ili CH3 i R2 je H ili CH3.
12. Spoj u skladu s patentnim zahtjevom 1 do 11, naznačen time što n je 0 ili 1.
13. (R,R)-Stereoizomer, naznačen time što je stereoizomer spoja u skladu s bilo kojim od patentnih zahtjeva 1 do 12.
14. Spoj u skladu s bilo kojim od patentnih zahtjeva 1 do 13, naznačen time što (CH2)n-C(=O)Q1 skupina je na meta položaju.
15. Spoj u skladu s patentnim zahtjevom 1, naznačen time što ga se bira iz skupine koju čine N-Benzil-2-(3-{2-[(2R)-2-(3-formilamino-4-hidroksifenil)-2-hidroksietilamino]-2-metilpropil}fenil)acetamid; N-(3,4-Dimetilbenzil)-2-(3-{2-[(2R)-2-(3-formilamino-4-hidroksifenil)-2-hidroksietilamino]-2-metilpropil}fenil)acetamid; N-[2-(4-Klorfenil)etil]-3-{2-[(2R)-2-(3-formilamino-4-hidroksifenil)-2-hidroksietilamino]-2-metilpropil}benzamid; N-[2-(2-Klorfenil)etil]-3-{2-[(2R)-2-(3-formilamino-4-hidroksifenil)-2-hidroksietilamino]-2-metilpropil}benzamid; 3-{2-[(2R)-2-(3-Formilamino-4-hidroksifenil)-2-hidroksietilamino]-2-metilpropil}-N-(2-naftalen-1-iletil)benzamid; 3-{2-[(2R)-2-(3-Formilamino-4-hidroksifenil)-2-hidroksietilamino]-2-metilpropil}-N-[2-(4-metilfenil)etil]benzamid; N-[2-(2,6-Dimetilfenil)etil]-3-{2-[(2R)-2-(3-formilamino-4-hidroksifenil)-2-hidroksietilamino]-2-metilpropil}benzamid; N-[2-(2,3-Dimetilfenil)etil]-3-{2-[(2R)-2-(3-formilamino-4-hidroksifenil)-2-hidroksietilamino]-2-metilpropilbenzamid; 3-{2-[(2R)-2-(3-Formilamino-4-hidroksifenil)-2-hidroksietilamino]-2-metilpropil}-N-[2-(4-hidroksi-2,3-dimetilfenil)etil]benzamid; 3-{2-[(2R)-2-(3-Formilamino-4-hidroksifenil)-2-hidroksietilamino]-2-metilpropil}-N-[2-(4-metoksifenil)etil]benzamid; 3-{2-[(2R)-2-(3-Formilamino-4-hidroksifenil)-2-hidroksietilamino]-2-metilpropil}-N-fenetilbenzamid; N-Cikloheksilmetil-3-{2-[(2R)-2-(3-formilamino-4-hidroksifenil)-2-hidroksietilamino]-2-metilpropil}benzamid; N-[5-((1R)-2-{1,1-Dimetil-2-[3-(piperidine-1-karbonil)fenil]etilamino}-1-hidroksietil)-2-hidroksifenil]formamid; 3-{2-[(2R)-2-(3-Formilamino-4-hidroksifenil)-2-hidroksietilamino]-2-metilpropil}-N-[2-(3-trifluorometilfenil)etil]benzamid; 3-{2-[(2R)-2-(3-Formilamino-4-hidroksifenil)-2-hidroksietilamino]-2-metilpropil}-N-(3-fenilpropil)benzamid; 3-{2-[(2R)-2-(3-Formilamino-4-hidroksifenil)-2-hidroksietilamino]-2-metilpropil}-N-indan-2-ilbenzamid; 3-{2-[(2R)-2-(3-Formilamino-4-hidroksifenil)-2-hidroksietilamino]-2-metilpropil}-N-(2-piridin-2-iletil)benzamid; 3-{2-[(2R)-2-(3-Formilamino-4-hidroksicyfenil)-2-hidroksietilamino]-2-metilpropil}-N-[2-(4-sulfamoilfenil)etil]benzamid; N-(4-Dimetilaminobenzil)-2-(3-{(2R)-2-[(2R)-2-(3-formilamino-4-hidroksifenil)-2-hidroksietilamino]propil}fenil)acetamid; N-[5-(2-{(1R)-2-[3-(3,4-Dihidro-1H-izokinoline-2-karbonil)fenil]-1,1-dimetiletilamino}-1-hidroksietil)-2-hidroksifenil]formamid; 3-{2-[(2R)-2-(3-Formilamino-4-hidroksifenil)-2-hidroksietilamino]-2-metilpropil}-N-(4'-hidroksibifenil-3-ilmetil)benzamid; 3-{2-[(2R)-2-(3-Formilamino-4-hidroksifenil)-2-hidroksietilamino]-2-metilpropil}-N-[2-(4-hidroksi-2,5-dimetilfenil)etil]benzamid; 3-{2-[(2R)-2-(3-Formilamino-4-hidroksifenil)-2-hidroksietilamino]-2-metilpropil}-N-[2-(4-hidroksi-3-metilfenil)etil]benzamid; N-(4-Acetilaminobenzil)-2-(3-{(2R)-2-[(2R)-2-(3-formilamino-4-hidroksifenil)-2-hidroksietilamino]propil}fenil)acetamid; 4-{[2-(3-{(2R)-2-[(2R)-2-(3-Formilamino-4-hidroksifenil)-2-hidroksietilamino]propil}fenil)acetilamino]metil}benzamid; N-Adamantan-1-il-3-{2-[(2R)-2-(3-formilamino-4-hidroksifenil)-2-hidroksietilamino]-2-metilpropil}benzamid; 3-{2-[(2R)-2-(3-Formilamino-4-hidroksifenil)-2-hidroksietilamino]-2-metilpropil}-N-(2-hidroksinaftalen-1-ilmetil)benzamid; 3-{2-[(2R)-2-(3-Formilamino-4-hidroksifenil)-2-hidroksietilamino]-2-metilpropil}-N-(4-hidroksi-3,5-dimetilbenzil)benzamid; 3-{2-[(2R)-2-(3-Formilamino-4-hidroksifenil)-2-hidroksietilamino]-2-metilpropil}-N-(6-hidroksinaftalen-2-ilmetil)benzamid; N-(3,6-Diklor-2-hidroksibenzil)-3-{2-[(2R)-2-(3-formilamino-4-hidroksifenil)-2-hidroksietilamino]-2-metilpropil}benzamid; N-(3,4-Dimetilbenzil)-2-(3-{2-[(2R)-2-(3-formilamino-4-hidroksifenil)-2-hidroksietilamino]etil}fenil)acetamid; 3-{2-[(2R)-2-(3-Formilamino-4-hidroksifenil)-2-hidroksietilamino]-2-metilpropil}-N-[2-(4-hidroksifenil)-2-metilpropil]benzamid; 3-{2-[(2R)-2-(3-Formilamino-4-hidroksifenil)-2-hidroksietilamino]-2-metilpropil}-N-(4'-hidroksibifenil-4-ilmetil)benzamid; N-Adamantan-1-il-2-(3-{(2R)-2-[(2R)-2-(3-formilamino-4-hidroksifenil)-2-hidroksietilamino]propil}fenil)acetamid; N-[5-(2-{2-[3-(10-Azatriciklo[6.3.1.02,7]dodeka-2(7),3,5-trien-10-karbonil)fenil]-1,1-dimetiletilamino}-1-hidroksietil)-2-hidroksifenil]formamid; 2-(3-{(2R)-2-[(2R)-2-(3-Formilamino-4-hidroksifenil)-2-hidroksietilamino]propil}fenil)-N-(4'-hidroksibifenil-3-ilmetil)acetamid; Metilni ester 4-{[2-(3-{2-[(2R)-2-(3-Formilamino-4-hidroksifenil)-2-hidroksietilamino]-2-metilpropil}fenil)acetilamino]metil}benzojeve kieseline; 2-(3-{(2R)-2-[(2R)-2-(3-Formilamino-4-hidroksifenil)-2-hidroksietilamino]-2-metilpropil}fenil)-N-(4-trifluorometoksibenzil)acetamid; N-(2-Klor-4-hidroksibenzil)-N-etil-2-(3-{(2R)-2-[(2R)-2-(3-formilamino-4-hidroksifenil)-2-hidroksietilamino]-2-metilpropil}fenil)acetamid; N-(2-Klor-4-hidroksibenzil)-2-(3-{(2R)-2-[(2R)-2-(3-formilamino-4-hidroksifenil)-2-hidroksietilamino]-2-metilpropil}fenil)acetamid; 2-(3-{(2R)-2-[(2R)-2-(3-Formilamino-4-hidroksifenil)-2-hidroksietilamino]propil}fenil)-N-(4-hidroksi-3,5-dimetilbenzil)acetamid; 2-(3-{(2R)-2-[(2R)-2-(3-Formilamino-4-hidroksifenil)-2-hidroksietilamino]propil}fenil)-N-(2-hidroksinaftalen-1-ilmetil)acetamid; N-(5-Klor-2-hidroksibenzil)-2-(3-{(2R)-2-[(2R)-2-(3-formilamino-4-hidroksifenil)-2-hidroksietilamino]propil}fenil)acetamid; N-(3,5-Diklor-2-hidroksibenzil)-2-(3-{(2R)-2-[(2R)-2-(3-formilamino-4-hidroksifenil)-2-hidroksietilamino]propil}fenil)acetamid; 2-(3-{(2R)-2-[(2R)-2-(3-Formilamino-4-hidroksifenil)-2-hidroksietilamino]propil}fenil)-N-(6-hidroksinaftalen-2-ilmetil)acetamid; 2-(3-{(2R)-2-[(2R)-2-(3-Formilamino-4-hidroksifenil)-2-hidroksietilamino]propil}fenil)-N-(4'-hidroksibifenil-4-ilmetil)acetamid; N-(4-Cijanobenzil)-2-(3-{2-[(2R)-2-(3-formilamino-4-hidroksifenil)-2-hidroksietilamino]-2-metilpropil}fenil)acetamid; 2-(3-{2-[(2R)-2-(3-Formilamino-4-hidroksifenil)-2-hidroksietilamino]-2-metilpropil}fenil)-N-(4-methanesulfonilbenzil)acetamid; 2-(3-{2-[(2R)-2-(3-Formilamino-4-hidroksifenil)-2-hidroksietilamino]-2-metilpropil}fenil)-N-(4-metilsulfanilbenzil)acetamid; 2-(3-{2-[(2R)-2-(3-Formilamino-4-hidroksifenil)-2-hidroksietilamino]-2-metilpropil}fenil)-N-(4-trifluorometilbenzil)acetamid; 2-(3-{2-[(2R)-2-(3-Formilamino-4-hidroksifenil)-2-hidroksietilamino]-2-metilpropil}fenil)-N-(4'-hidroksibifenil-4-ilmetil)acetamid; N-[2-(5-Klor-2-hidroksifenil)etil]-3-{2-[(2R)-2-(3-formilamino-4-hidroksifenil)-2-hidroksietilamino]-2-metilpropil}benzamid; 2-(3-{2-[(2R)-2-(3-Formilamino-4-hidroksifenil)-2-hidroksietilamino]-2-metilpropil}fenil)-N-(4'-hidroksibifenil-3-ilmetil)acetamid; 3-{2-[(2R)-2-(3-Formilamino-4-hidroksifenil)-2-hidroksietilamino]propil}-N-[2-(4-hidroksifenil)-2-metilpropil]benzamid; N-(2-Klor-4-hidroksibenzil)-2-(3-{(2R)-2-[(2R)-(2R)-2-(3-formilamino-4-hidroksifenil)-2-hidroksietilamino]propil}fenil)acetamid; N-[2-(5-Klor-2-hidroksifenil)etil]-3-{2-[(2R)-2-(3-formilamino-4-hidroksifenil)-2-hidroksietilamino]-2-metilpropil}benzamid; 3-{2-[(2R)-2-(3-Formilamino-4-hidroksifenil)-2-hidroksietilamino]propil}-N-[2-(4-hidroksifenil)-2-metilpropil]benzamid; 2-(3-{2-[(2R)-2-(3-Formilamino-4-hidroksifenil)-2-hidroksietilamino]-2-metilpropil}fenil)-N-(tetrahidro-tiopiran-4-il)acetamid; N-(5-Klor-2-hidroksibenzil)-2-(3-{2-[(2R)-2-(3-formilamino-4-hidroksifenil)-2-hidroksietilamino]-2-metilpropil}fenil)acetamid; i N-{5-[(1R)-2-((1R)-2-{3-[3-(3,4-Dihidro-1H-izokinolin-2-il)-3-oksopropil]fenil}-1-metiletilamino)-1-hidroksietil]-2-hidroksifenil}formamid.
16. Spoj, naznačen time što je N-(5-klor-2-hidroksibenzil)-2-(3-{(2R)-2-[(2R)-2-(3-formilamino-4-hidroksifenil)-2-hidroksietilamino]propil}fenil)acetamid ili njegova farmaceutski prihvatljiva sol ili solvat.
17. Spoj, naznačen time što je 2-(3-{(2R)-2-[(2R)-2-(3-formilamino-4-hidroksifenil)-2-hidroksietilamino]propil}fenil)-N-(4-hidroksi-3,5-dimetilbenzil)acetamid ili njegova farmaceutski prihvatljiva sol ili solvat.
18. Spoj, naznačen time što je 2-(3-{(2R)-2-[(2R)-2-(3-formilamino-4-hidroksifenil)-2-hidroksietilamino]propil}fenil)-N-(6-hidroksinaftalen-2-ilmetil)acetamid ili njegova farmaceutski prihvatljiva sol ili solvat.
19. Spoj, naznačen time što je 2-(3-{(2R)-2-[(2R)-2-(3-formilamino-4-hidroksifenil)-2-hidroksietilamino]propil}fenil)-N-(4'-hidroksibifenil-4-ilmetil)acetamid ili njegova farmaceutski prihvatljiva sol ili solvat.
20. Spoj, naznačen time što je N-[2-(4-klorfenil)etil]-3-{2-[(2R)-2-(3-formilamino-4-hidroksifenil)-2-hidroksietilamino]-2-metilpropil}benzamid ili njegova farmaceutski prihvatljiva sol ili solvat.
21. Farmaceutski pripravak, naznačen time što u najmanjeu ruku sadrži djelotvornu količinu spoja formule (1) u skladu s bilo kojim od patentnih zahtjeva 1 do 20 ili njegovu farmaceutski prihvatljivu sol ili izvedeni oblik.
22. Spoj formule (1) u skladu s bilo kojim od patentnih zahtjeva 1 do 20 ili njegova farmaceutski prihvatljiva sol, izvedeni oblik ili pripravak, naznačen time što je namijenjen upotrebi kao medikament.
23. Upotreba spoja formule (1) u skladu s bilo kojim od patentnih zahtjeva 1 do 20 ili njegove farmaceutski prihvatljive soli, izvedenog oblika ili pripravaka, naznačena time što je navedeni spoj namijenjen proizvodnji lijeka za liječenje bolesti, poremećaja i stanja koje se bira iz skupine koju čine: • astma bilo kojeg tipa, etiologije ili patogeneze, osobito astma koja je član kojeg se bira iz skupine koju čine atopična astma, neatopična astma, alergijska astma, atopična bronhijalna astma posredovana IgE-om, bronhijalna astma, esencijalna astma, prava astma, intrinzična astma, uzrokovana patofiziološkim poremećajima, ekstrinzična astma, uzrokovana čimbenicima iz okoliša, esencijalna astma nepoznatog ili neočiglednog uzroka, neatopična astma, bronhitična astma, emfizematozna astma, astma izazvana fizičkom aktivnošću, astma izazvana alergenima, astma izazvana hladnim zrakom, profesionalna astma, infektivna astma, uzrokovana bakterijskom, gljivičnom, protozojskom ili virusnom infekcijom, nealergijska astma, incipijentna astma, sindrom sopljućeg djeteta i bronhiolitis, • kronična ili akutna bronhokonstrikcija, kronični bronhitis, začepljenje malih dišnih puteva, te emfizem, • opstruktivne ili upalne bolesti dišnih puteva bilo kojeg tipa, etiologije ili patogeneze, osobito opstruktivna ili upalna bolest dišnih puteva koja je član kojeg se bira iz skupine koju čine kronična eozinofilna pneumonija, kronična opstruktivna plućna bolest (COPD), COPD koji uključuje kronični bronhitis, plućni emfizem ili dispneju povezane ili nepovezane s COPD-om, COPD kod kojeg je karakteristično nepovratno, progresivno začepljenje dišnih puteva, sindrom respiratornog distresa kod odraslih (ARDS), pogoršanje preosjetljivosti dišnih puteva zbog terapije drugim lijekovima i bolest dišnih puteva povezana s plućnom hipertenzijom, • bronhitis bilo kojeg tipa, etiologije ili patogeneze, osobito bronhitis koji je član kojeg se bira iz skupine koju čine akutni bronhitis, akutni laringotrahealni bronhitis, arahidni bronhitis, kataralni bronhitis, krupozni bronhitis, suhi bronhitis, infektivni astmatični bronhitis, produktivni bronhitis, stafilokokni ili streptokokni bronhitis i vezikularni bronhitis, • akutna ozljada pluća, • bronhiektazija bilo kojeg tipa, etiologije ili patogeneze, osobito bronhiektazija koja je član kojeg se bira iz skupine koju čine cilindrična bronhiektazija, sakularna bronhiektazija, fuziformna bronhiektazija, kapilarna bronhiektazija, cistična bronhiektazija, suha bronhiektazija i folikularna bronhiektazija.
24. Kombinacija spoja u skladu s bilo kojim od patentnih zahtjeva 1 do 20, naznačena time što se navedeni spoj kombinira s jednim ili više drugih terapeutijskih sredstava, koja sebira između: (a) Inhibitora 5-lipoksigenaze (5-LO) ili antagonista 5-lipoksigenaza-aktivirajućeg proteina (FLAP), (b) Leukotrienskim antagonistima (LTRA), uključujući antagoniste LTB4, LTC4, LTD4 i LTE4, (c) Antagonistima histaminskih receptora, uključujući H1 i H3 antagoniste, (d) α1- i α2-adrenoceptorskim vazokonstrikcijskim simpatomimetskim agonistima koje se upotrebljava kao dekongestivi, (e) Antagonistima muskarinskog receptora M3 ili antikolinergičkim sredstvima, (f) Inhibitorima PDE, primjerice inhibitorima PDE3, PDE4 i PDE5, (g) Teofilinom, (h) Natrijevom kromoglikatom, (i) Inhibitorima COX, kako neselektivnim tako i selektivnim inhibitorima COX-1 ili COX-2 (NSAID), (j) Oralnim i inhalacijskim glukokortikosteroidima, (k) Monoklonskim protutijelima aktivnim protiv endogenih upalnih entiteta, (l) Sredstva protiv čimbenika tumorske nekroze (anti-TNF-α), (m) Inhibitorima adhezijskih molekula, uključujući antagoniste VLA-4, (n) Antagonistima kininskih receptora B1 i B2, (o) Imunosupresivnim sredstvima, (p) Inhibitorima matriksnih metaloproteaza (MMP), (q) Antagonistima tahikininskih receptora NK1, NK2 i NK3, (r) Inhibitorima elastaze, (s) Adenosine A2a receptor agonisti, (t) Inhibitorima urokinaze, (u) Spojevima koji djeluju na dopaminske receptore, primjerice D2 agonistima, (v) Modulatorima NFκβ puta, primjerice inhibitorima IKK, (w) Modulatorima citokinskih signalnih puteva, poput p38 MAP kinaze ili syk kinaze, (x) Sredstima koja se može klasificirati kao mukolitike ili antitusike, (y) Antibioticima, (z) Inhibitorima HDAC, i, (aa) Inhibitorima PI3-kinaze.
HR20100402T 2004-03-23 2010-07-20 Formamidni derivati korisni kao ardrenoceptor HRP20100402T1 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP04290767 2004-03-23
GB0425054A GB0425054D0 (en) 2004-03-23 2004-11-12 Formamide derivatives for the treatment of diseases
PCT/IB2005/000619 WO2005092840A1 (en) 2004-03-23 2005-03-10 Formamide derivatives useful as adrenoceptor

Publications (1)

Publication Number Publication Date
HRP20100402T1 true HRP20100402T1 (hr) 2010-09-30

Family

ID=35432183

Family Applications (1)

Application Number Title Priority Date Filing Date
HR20100402T HRP20100402T1 (hr) 2004-03-23 2010-07-20 Formamidni derivati korisni kao ardrenoceptor

Country Status (30)

Country Link
JP (2) JP4033892B2 (hr)
KR (1) KR100806478B1 (hr)
AR (1) AR050236A1 (hr)
AT (1) ATE469121T1 (hr)
CA (1) CA2560547C (hr)
CY (1) CY1112549T1 (hr)
DE (1) DE602005021472D1 (hr)
DK (1) DK1730103T3 (hr)
DO (1) DOP2005000045A (hr)
EA (1) EA010133B1 (hr)
ES (1) ES2343808T3 (hr)
GB (1) GB0425054D0 (hr)
GE (1) GEP20084455B (hr)
HN (1) HN2005000118A (hr)
HR (1) HRP20100402T1 (hr)
IL (1) IL178102A (hr)
IS (1) IS8552A (hr)
MA (1) MA28480B1 (hr)
MX (1) MXPA06011019A (hr)
MY (1) MY144103A (hr)
NL (1) NL1028597C2 (hr)
NO (1) NO20064806L (hr)
NZ (1) NZ549839A (hr)
PE (1) PE20060264A1 (hr)
PT (1) PT1730103E (hr)
RS (1) RS51438B (hr)
SI (1) SI1730103T1 (hr)
SV (1) SV2005002056A (hr)
TW (1) TWI335312B (hr)
UY (1) UY28819A1 (hr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8481569B2 (en) 2008-04-23 2013-07-09 Takeda Pharmaceutical Company Limited Iminopyridine derivatives and use thereof

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2005492A6 (es) * 1987-12-23 1989-03-01 Lasa Lab Procedimiento de obtencion de n-(2-hidroxi-5-(1-hidroxi-2((2- (4-metoxifenil)-1metiletil)amino)etil)fenil)foramida (i).
CH686869A5 (de) * 1991-04-05 1996-07-31 Sepracor Inc Beta (2) -bronchienerweiternde Arzneistoffe in Form ihrer Bronchienerweiternden Enantiomeren zur Verwendung fuer die Herstellung eines Mittels zur verbesserten Therapie.
UA73965C2 (en) * 1999-12-08 2005-10-17 Theravance Inc b2 ADRENERGIC RECEPTOR ANTAGONISTS
OA11558A (en) * 1999-12-08 2004-06-03 Advanced Medicine Inc Beta 2-adrenergic receptor agonists.
US6653323B2 (en) * 2001-11-13 2003-11-25 Theravance, Inc. Aryl aniline β2 adrenergic receptor agonists
TWI249515B (en) * 2001-11-13 2006-02-21 Theravance Inc Aryl aniline beta2 adrenergic receptor agonists
JP2005527618A (ja) * 2002-05-28 2005-09-15 セラヴァンス インコーポレーテッド アルコキシアリールβ２アドレナリン作動性レセプターアゴニスト
EP1615881A2 (en) * 2003-04-01 2006-01-18 Theravance, Inc. Diarylmethyl and related compounds having beta2 adrenergic receptor agonist and muscarinic receptor antagonist activity
US7268147B2 (en) * 2003-05-15 2007-09-11 Pfizer Inc Compounds useful for the treatment of diseases
CA2553789C (en) * 2004-01-22 2011-07-19 Pfizer Inc. Sulfonamide derivatives for the treatment of diseases
WO2005092861A1 (en) * 2004-03-11 2005-10-06 Pfizer Limited Quinolinone derivatives pharmaceutical compositions containing them and their use
EA200601510A1 (ru) * 2004-03-17 2007-04-27 Пфайзер Инк. Производные фенилэтаноламина в качестве бета-2-агонистов
WO2005092841A1 (en) * 2004-03-23 2005-10-06 Pfizer Limited Compounds having beta-agonist activity
CA2560368A1 (en) * 2004-03-23 2005-10-06 Pfizer Inc. Compounds for the treatment of diseases

Also Published As

Publication number Publication date
IS8552A (is) 2006-10-10
TW200531959A (en) 2005-10-01
JP2007530524A (ja) 2007-11-01
UY28819A1 (es) 2005-10-31
CY1112549T1 (el) 2015-12-09
JP2008056680A (ja) 2008-03-13
IL178102A (en) 2011-08-31
SV2005002056A (es) 2005-12-13
IL178102A0 (en) 2006-12-31
PE20060264A1 (es) 2006-04-01
JP4033892B2 (ja) 2008-01-16
MXPA06011019A (es) 2007-03-21
DOP2005000045A (es) 2005-11-15
NO20064806L (no) 2006-12-21
MA28480B1 (fr) 2007-03-01
ATE469121T1 (de) 2010-06-15
NZ549839A (en) 2010-01-29
GB0425054D0 (en) 2004-12-15
GEP20084455B (en) 2008-08-10
JP4819770B2 (ja) 2011-11-24
NL1028597A1 (nl) 2005-09-26
HN2005000118A (es) 2011-02-25
TWI335312B (en) 2011-01-01
CA2560547A1 (en) 2005-10-06
KR20060122969A (ko) 2006-11-30
EA200601544A1 (ru) 2007-02-27
NL1028597C2 (nl) 2006-03-06
EA010133B1 (ru) 2008-06-30
PT1730103E (pt) 2010-07-21
MY144103A (en) 2011-08-15
SI1730103T1 (sl) 2010-09-30
DK1730103T3 (da) 2010-08-16
ES2343808T3 (es) 2010-08-10
KR100806478B1 (ko) 2008-02-21
DE602005021472D1 (de) 2010-07-08
RS51438B (en) 2011-04-30
CA2560547C (en) 2011-02-01
AR050236A1 (es) 2006-10-11

Similar Documents

Publication Publication Date Title
CA2553789A1 (en) Sulfonamide derivatives for the treatment of diseases
CA2553293A1 (en) Sulfonamide derivatives for the treatment of diseases
JP2009530364A5 (hr)
JP2006511596A5 (hr)
NL1028599C2 (nl) Verbindingen voor de behandeling van ziekten.
CA2643097A1 (en) Amine derivatives
JP2007529499A5 (hr)
JP3966897B2 (ja) ベータ２アゴニストとしての（２−ヒドロキシ−２−（４−ヒドロキシ−３−ヒドロキシメチルフェニル）−エチルアミノ）−プロピル−フェニル誘導体
RU2009118825A (ru) ПРОИЗВОДНЫЕ 4-(2-АМИНО-1ГИДРОКСИЭТИЛ)ФЕНОЛА В КАЧЕСТВЕ АГОНИСТОВ β2-АДРЕНЕРГИЧЕСКОГО РЕЦЕПТОРА
HRP20170307T1 (hr) NOVI DERIVATI CIKLOHEKSILAMINA KOJI POSJEDUJU DJELOVANJA AGONISTA ß2 ADRENERGIČKOG RECEPTORA I ANTAGONISTA M3 MUSKARINSKOG RECEPTORA
HRP20180116T1 (hr) (2s)-n-[(1s)-1-cijano-2-feniletil]-1,4-oksazepan-2-karboksamidi kao inhibitori dipeptidil peptidaze i
HRP20170896T1 (hr) Derivati pirimidina
JP2018199697A (ja) 粘膜への水分付与が不十分であることが好都合である疾患の治療に有用なクロロ−ピラジンカルボキサミド誘導体
CA2623332A1 (en) Carboxamide derivatives as muscarinic receptor antagonists
HRP20100035T1 (hr) Kristalni oblici bifenilnog spoja
JP4054366B2 (ja) 疾患の治療のために有用な化合物
CA2678683A1 (en) Hydrochloride salt of 5-[3-(3-hydroxyphenoxy)azetidin-1-yl]-5-methyl-2,2-diphenylhexanamide
HRP20130174T1 (hr) Derivati pirimidina za lijeäśenje astme, kopb, alergijskog rinitisa, alergijskog konjuktivitisa, atopijskog dermatitisa, karcinoma, hepatitisa b, hepatitisa c, hiv, hpv, bakterijskih infekcija i dermatoze
HRP20100020T1 (hr) Novi derivati hidantoina za liječenje opstruktivnih bolesti dišnih putova
JP2010520893A5 (hr)
HRP20120271T1 (hr) Novi p2x7r antagonisti i njihova uporaba
CA2560368A1 (en) Compounds for the treatment of diseases
CA2658359A1 (en) Heterocyclic compounds and methods of use
HRP20100433T1 (hr) Diazaindol-dikarbonil-piperazinil antivirotici
HRP20100402T1 (hr) Formamidni derivati korisni kao ardrenoceptor